Big Pharma Split Corp Class A (TO:PRM) — Stock Price
Big Pharma Split Corp Class A (TO:PRM) is currently trading at CA$14.96 CAD, up 1.42% today. Over the past 52 weeks, shares have ranged between CA$11.03 and CA$15.50. This page tracks Big Pharma Split Corp Class A's live share price on the TO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see PRM stock market capitalisation.
Big Pharma Split Corp Class A (PRM) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Big Pharma Split Corp Class A's daily closing share price and trading volume on the TO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Big Pharma Split Corp Class A Income Statement — Revenue, Profit & Earnings by Year
Big Pharma Split Corp Class A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CA$1.85 Million | CA$311.76K | CA$3.71 Million | CA$5.36 Million | CA$589.26K |
| Cost of Revenue | CA$315.95K | CA$308.57K | CA$419.54K | CA$355.99K | CA$277.31K |
| Gross Profit | CA$1.53 Million | CA$311.76K | CA$3.71 Million | CA$5.36 Million | CA$589.26K |
| Research & Development | — | — | — | — | — |
| SG&A | CA$540.84K | CA$334.55K | CA$357.76K | CA$370.56K | CA$216.25K |
| Total Operating Expenses | CA$540.84K | CA$451.44K | CA$565.13K | CA$505.73K | CA$323.83K |
| Operating Income | CA$13.41K | CA$-139.68K | CA$3.15 Million | CA$4.85 Million | CA$265.42K |
| EBITDA | CA$21.36K | CA$-137.56K | CA$3.15 Million | CA$4.85 Million | CA$265.42K |
| EBIT | — | CA$-500.80K | CA$3.15 Million | CA$4.85 Million | CA$265.42K |
| Interest Expense | CA$559.98K | CA$507.79K | CA$760.17K | CA$875.41K | CA$482.81K |
| Income Before Tax | CA$-538.62K | CA$-645.35K | CA$3.15 Million | CA$4.85 Million | CA$265.42K |
| Income Tax Expense | — | CA$-505.67K | CA$2.39 Million | CA$4.21 Million | CA$-217.39K |
| Net Income | CA$-538.62K | CA$-139.68K | CA$3.15 Million | CA$4.85 Million | CA$265.42K |
Big Pharma Split Corp Class A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Big Pharma Split Corp Class A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CA$26.30 Million | CA$26.53 Million | CA$39.10 Million | CA$37.81 Million | CA$22.93 Million |
| Total Current Assets | CA$1.13 Million | CA$999.54K | CA$14.82 Million | CA$1.53 Million | CA$335.25K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CA$25.17 Million | CA$718.24K | CA$23.73 Million | CA$35.32 Million | CA$22.40 Million |
| Net Receivables | CA$96.74K | CA$77.11K | CA$14.00 Million | CA$102.62K | CA$104.25K |
| Inventory | — | CA$-718.24K | CA$-545.14K | CA$-964.14K | CA$-194.46K |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CA$12.62 Million | CA$10.68 Million | CA$19.37 Million | CA$15.41 Million | CA$9.75 Million |
| Total Current Liabilities | CA$11.84 Million | CA$248.68K | CA$19.37 Million | CA$339.02K | CA$9.75 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | CA$10.54 Million | CA$10.09 Million | CA$9.04 Million | CA$13.43 Million | CA$9.12 Million |
| Total Stockholder Equity | CA$13.68 Million | CA$15.85 Million | CA$19.73 Million | CA$22.40 Million | CA$13.19 Million |
| Retained Earnings | — | — | — | — | — |
Big Pharma Split Corp Class A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Big Pharma Split Corp Class A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CA$-1.30 Million | CA$11.86 Million | CA$1.13 Million | CA$-9.00 Million | CA$4.35 Million |
| Capital Expenditures | CA$3.00 | CA$3.00 | CA$0.00 | CA$0.00 | CA$3.00 |
| Free Cash Flow | CA$-1.30 Million | CA$11.86 Million | CA$1.13 Million | CA$-9.00 Million | CA$4.35 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | CA$-346.38K | CA$-12.47 Million | CA$-1.74 Million | CA$10.19 Million | CA$-4.65 Million |
| Dividends Paid | CA$1.50 Million | CA$2.11 Million | CA$2.62 Million | CA$2.84 Million | CA$1.23 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | — | — | — | — | — |
| Change in Cash | CA$826.45K | CA$-615.02K | CA$-610.61K | CA$1.20 Million | CA$-305.06K |
Big Pharma Split Corp Class A Earnings History — EPS Actual vs. Analyst Estimates
Track Big Pharma Split Corp Class A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for Big Pharma Split Corp Class A.